GENB
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Graham Number and Intrinsic Value are unavailable due to lack of positive earnings and equity.
- P/S of 46.08 is unsustainable
- Negative P/B ratio
- No earnings for P/E calculation
Future value is based entirely on analyst projections rather than historical growth trends.
- High analyst target price ($25)
- Strong Buy recommendation
- No provided revenue growth data to support valuation
Consistent downward price performance across all measured intervals.
- Negative returns across 1Y, 6M, and 1M timeframes
- Recent 1-week drop of 16.1%
Liquidity is strong, but profitability and solvency (equity) are critical concerns.
- Current Ratio 2.85
- Quick Ratio 2.69
- Piotroski F-Score 4/9 (Stable but weak)
- ROE of -81.72%
Typical for growth-stage biotech; no income component.
- No dividend yield
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for GENB and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
GENB
Generate Biomedicines, Inc.
Primary
|
-8.8% | -8.8% | -8.8% | -8.8% | -5.6% | -16.1% |
|
GLUE
Monte Rosa Therapeutics, Inc.
Peer
|
-14.8% | +121.2% | +344.6% | +113.4% | +4.5% | +5.6% |
|
AVAH
Aveanna Healthcare Holdings Inc.
Peer
|
-42.4% | +506.1% | +26.3% | -14.5% | -9.6% | -1.7% |
|
AHCO
AdaptHealth Corp.
Peer
|
-72.3% | -20.2% | +10.2% | +14.1% | +0.5% | +11.6% |
|
BCRX
BioCryst Pharmaceuticals, Inc.
Peer
|
-25.9% | -38.3% | -12.2% | -20.6% | -11.8% | +1.9% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
GENB
Generate Biomedicines, Inc.
|
BEARISH | $1.47B | - | -81.7% | -% | $11.53 | |
|
GLUE
Monte Rosa Therapeutics, Inc.
|
NEUTRAL | $1.44B | - | -16.9% | -31.2% | $18.05 | Compare |
|
AVAH
Aveanna Healthcare Holdings Inc.
|
BEARISH | $1.44B | 18.68 | -% | 3.3% | $6.91 | Compare |
|
AHCO
AdaptHealth Corp.
|
BEARISH | $1.44B | - | -4.3% | -2.2% | $10.6 | Compare |
|
BCRX
BioCryst Pharmaceuticals, Inc.
|
NEUTRAL | $1.43B | - | -% | -1.5% | $6.79 | Compare |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning GENB from our newsroom.